Dow Reclaims 16,000 as AT&T, UnitedHealth Lead Gains
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.
The Dow Jones Industrials passed another milestone today in its attempt to recover from its January losses, climbing back above the 16,000 mark with a gain of almost 64 points. Without any obvious far-reaching rationale for the gains, investors found hot stories across all of the Dow's sectors, as AT&T and UnitedHealth outpaced the Dow on a percentage basis. Nike and Boeing also rose more than 1%, showing the breadth of the advance.
AT&T's 1.7% gain came apparently at the expense of rival Verizon, which announced a change in the pricing structure with its "More Everything" plan. With Verizon making most of its savings contingent on customers choosing its Edge plan, the value of the plan isn't as apparent as some of the changes that AT&T and other rivals have made to their offerings. If AT&T can actually win a price-war against Verizon, it could potentially threaten Verizon's No. 1 position in the U.S. wireless market -- all the while paying investors the best dividend yield in the Dow Jones Industrial Average.
For UnitedHealth, news that enrollment under plans in the Affordable Care Act had risen in January might have played a key role in pushing shares up about 1.4%. UnitedHealth rival WellPoint said that the figures were consistent with its expectations, and its shares saw similar gains to those of UnitedHealth. Still, there's a lot uncertainty remaining about how Obamacare's rollout will fare as the key March 31 deadline approaches, and so the jury's still out on whether UnitedHealth's more conservative approach to the health-insurance exchanges will prove better than WellPoint's more aggressive exchange strategy.
Meanwhile, Nike's and Boeing's respective gains largely seem to reflect their underlying fundamental strength. For Nike, brand awareness has been a key component of its fight against up-and-coming rivals in the athletic apparel and footwear industry. With such a strong lineup of endorsement talent behind its products, Nike would have to misstep badly in order to give up its head start, but it also can't afford to stop innovating. Similarly, Boeing has a huge opportunity with trillions of dollars of potential future sales in the balance, and its efforts to boost efficient production of all the aircraft its customers have already ordered could well bear fruit for years, if not decades, to come. Doing so, though, requires enough discipline to avoid what could be costly mistakes if things go wrong.
Dow 16,000 is a reality once more, but some investors still wonder whether it will last. For now, though, most investors appear convinced that the correction is over and that it's back to the normal full-speed-ahead mode that we've seen for years.
These stocks don't need Dow 16,000 in order to soar
Find consistent outperformance in growth stocks? They said it couldn't be done. But David Gardner has proved them wrong, time, and time, and time again, with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
The article Dow Reclaims 16,000 as AT&T, UnitedHealth Lead Gains originally appeared on Fool.com.
Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Nike and UnitedHealth Group. The Motley Fool owns shares of Nike. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.